Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds a...

詳細記述

書誌詳細

主要な著者:	Elio Gregory Pizzutilo, MD, Alberto Giuseppe Agostara, MD, Laura Roazzi, MD, Rebecca Romanò, MD, Valentina Motta, PhD, Calogero Lauricella, PhD, Giovanna Marrapese, PhD, Giulio Cerea, MD, Diego Signorelli, MD, PhD, Silvio Marco Veronese, PhD, Laura Giuseppina Giannetta, MD, Andrea Sartore-Bianchi, MD, Salvatore Siena, MD
フォーマット:	Artigo
言語:	Inglês
出版事項:	Elsevier 2023-11-01
シリーズ:	JTO Clinical and Research Reports
主題:	Case report Entrectinib Repotrectinib Resistance ROS1 F2004V
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S266636432300098X
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!